CURRENTLY OPEN CLINICAL TRIALS:
GENERAL CANCER CONTROL TRIALS for SYMPTOM MANAGEMENT:
20060392 Health Resources Utilization Associated with Skeletal Related Events in Patients with Bone Metastases Secondary to Breast, Prostate, or Lung Cancer, or Multiple Myeloma. download schema and patient eligibility summary
N07C2 Wisconsin Ginseng to Improve Cancer-Related Fatigue. download schema and patient eligibility summary
N08C1 Taxol-associated Acute Pain Syndrome Natural History Study. download schema and patient eligibility summary
N08C3 Gabapentin for the Prevention of Delayed Chemotherapy Induced Nausea and Vomiting in Patients Receiving Highly Emetogenic Chemotherapy. download schema and patient eligibility summary
RTOG-0517 Radiopharmaceuticals and Zometa in the Palliation of Osteoblastic Metastases from Lung, Breast, and Prostate Cancer. download schema and patient eligibility summary
S0702 Assess the Incidence of Osteonecrosis of the Jaw in Cancer Patients with Bone Metastases Starting Zometa Treatment. download schema and patient eligibility summary
URCC-04-02 Prevention of Delayed Nausea. download schema and patient eligibility summary
CLINICAL TRIALS BY DISEASE SITE:
BRAIN:
N0776 Avastin in Combination with Nexavar in Recurrent Glioblastoma Multiforme. download schema and patient eligibility summary
N0779 Zolinza in Combination with Velcade in Patients with Recurrent Glioblastoma Multiforme. download schema and patient eligibility summary
BREAST:
BREAST CANCER CONTROL:
AVF4349n Observational Study of Treatment Patterns and Safety Outcomes for Metastatic or Locally Recurrent Breast Cancer. download schema and patient eligibility summary
CALGB-70301 Quality of Life, Employment and Informal Care Cost Analysis in Women Receiving Adjuvant Chemotherapy for Node-Negative Breast Cancer. download schema and patient eligibility summary
CZOL446E2352 Continued Efficacy and Safety of Zometa (every 4 weeks vs every 12 weeks) in Patients with Documented Bone Metastases from Breast Cancer. download schema and patient eligibility summary
S0715 Acetyl-L-Carnitine (ALC) for the Prevention of Taxane Induced Neuropathy. download schema and patient eligibility summary
HER2+:
ACOSOG-Z1041 Comparing a Neoadjuvant Regimen of FEC-75 Followed By Taxol Plus Herceptin with a Neoadjuvant Regimen of Taxol Plus Herceptin Followed By FEC-75 Plus Herceptin in Patients with HER-2 Positive Palpable and Operable Breast Cancer. download schema and patient eligibility summary
B-41-I Neoadjuvant Therapy for Patients with Palpable and Operable HER2-Positive Breast Cancer Comparing the Combination of Herceptin Plus Tykerb to Herceptin and to Tykerb Administered with Weekly Taxol Following AC Accompanied by Correlative Science Studies to Identify Predictors of Pathologic Complete Response. download schema and patient eligibility summary
B-44-I Adjuvant Therapy for Patients with HER2-Positive Node-Positive or High Risk Node-Negative Breast Cancer Comparing Chemotherapy Plus Herceptin with Chemotherapy Plus Herceptin Plus Avastin. download schema and patient eligibility summary
CALGB-40601 Taxol Combined with Herceptin, Tykerb, or Both as Neoadjuvant Treatment of HER-2 Positive Primary Breast Cancer. download schema and patient eligibility summary
N063D Adjuvant Tykerb, Herceptin, Their Sequence and Their Combination in Patients with HER2/ErbB2 Positive Primary Breast Cancer. download schema and patient eligibility summary
NSABP B-43 Herceptin Given Concurrently with Radiation Therapy vs Radiation Therapy Alone for Women with HER2-Positive Ductal Carcinoma In Situ Resected by Lumpectomy. download schema and patient eligibility summary
METASTATIC:
3144A1-2206WW Neratinib in Combination with Xeloda in Subjects with Solid Tumors and Erb-2 Positive Metastatic or Locally Advanced Breast Cancer. download schema and patient eligibility summary
N0735 Abraxane in Combination with Gemzar and Avastin in Patients with Metastatic Breast Cancer. download schema and patient eligibility summary
NODAL:
ACOSOG Z1071 Sentinel Lymph Node Surgery and Axillary Lymph Node Dissection Following Preoperative Chemotherapy in Women with Node Positive Breast Cancer at Initial Diagnosis. download schema and patient eligibility summary
CALGB-40101 Cytoxan & Adriamycin vs Taxol as Adjuvant Therapy for Women with Node-Positive Breast Cancer. download schema and patient eligibility summary
BREAST OTHER:
B-46-I TC Plus Avastin vs TC Alone vs TAC for Women with Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer. download schema and patient eligibility summary
CALGB-40502 Weekly Taxol Compared to Weekly Abraxane or Ixempra Combined with Avastin as First-line Therapy for Locally Recurrent or Metastatic Breast Cancer. download schema and patient eligibility summary
CALGB-40503 Endocrine Therapy Alone or Plus Avastin for Women with Hormone Receptor-Positive Advanced Breast Cancer. download schema and patient eligibility summary
FB-6 Four Cycles of Adriamycin and Cytoxan Followed by Weekly Taxol Given Concurrently with Pazopanib as Neoadjuvant Therapy Followed by Postoperative Pazopanib for Women with Locally Advanced Breast Cancer. download schema and patient eligibility summary
NSABP-B-40 Neoadjuvant Therapy in Patients with Palpable and Operable Breast Cancer Evaluating the Effect on Pathologic Complete Response (pCR) of Adding Xeloda or Gemzar to Taxotere when Administered Before AC with or without Avastin and Correlative Science Studies Attempting to Identify Predictors of High Likelihood for pCR with Each of the Regimens. download schema and patient eligibility summary
NSABP-B-42 Five Years of Femara vs Placebo in Patients Completing 5 Years of Hormonal Therapy Consisting of an Aromatase Inhibitor (AI) or Tamoxifen Followed by an AI in Postmenopausal Women with Hormone Receptor Positive Breast Cancer. download schema and patient eligibility summary
PACCT-1 Program for the Assessment of Clinical Cancer Tests: Trial Assigning Individualized Options for Treatment: The TAILORx Trial. download schema and patient eligibility summary
PACS-0610 Sequential Regimen Associating FEC100 and Ixempra in Adjuvant Treatment of Non-Metastatic, Poor Prognosis Breast Cancer Defined as Triple-Negative Tumor (HER2/ER/PR-) or HER2/PR- Tumor; in Node+ or Node- Patients. download schema and patient eligibility summary
S0307 Bisphosphonates as Adjuvant Therappy for Primary Breast Cancer. download schema and patient eligibility summary
GASTROINTESTINAL:
GASTROINTESTINAL CANCER CONTROL:
CSTI571BUS227 Gastrointestinal Stromal Tumors Registry Protocol.
COLORECTAL:
ACOSOG-Z6051 Laparoscopic-assisted Resection vs Open Resection for Rectal Cancer. download schema and patient eligibility summary
E5202 5-FU, Leucovorin and Oxaliplatin vs 5-FU, Leukovorin, Oxaliplatin and Avastin in Patients with Stage II Colon Cancer at High Risk for Recurrence to Determine Prospectively the Prognostic Value of Molecular Markers. download schema and patient eligibility summary
EFC10262 Comparing the Efficacy of VEGF Trap Once Every 2 Weeks vs Placebo in Patients with Metastatic Colorectal Cancer Treated with Camptosar/5-FU Combination after Failure of an Oxaliplatin Based Regimen. download schema and patient eligibility summary
N0147 Camptosar and/or Oxaliplatin Plus 5-FU/Leucovorin after Curative Resection for Patients with Stage III Colon Cancer. download schema and patient eligibility summary
NSABP-R-04 Preoperative Radiation Therapy(RT) and Xeloda vs Preoperative RT and Continuous Intravenous Infusion of 5-FU in the Treatment of Patients with Operable Carcinoma of the Rectum. download schema and patient eligibility summary
S0600 Irinotecan-based Chemotherapy + Cetuxan or Avastin as 2nd Line Therapy for Patients with Metastatic Colorectal Cancer who have Progressed on Avastin with Either FOLFOX, OPTIMOX, or XELOX. download schema and patient eligibility summary
S0713 Oxaliplatin, Xeloda, Erbitux and Radiation in Pre-operative Therapy of Rectal Cancer. download schema and patient eligibility summary
PANCREATIC:
ACOSOG-Z5041 Preoperative Gemzar and Tarceva Plus Pancreatectomy and Postoperative Gemzar and Tarceva for Patients with Operable Pancreatic Adenocarcinoma. download schema and patient eligibility summary
N064A Vectibix, Chemotherapy, and External Beam Radiation in Patients with Locally Advanced Pancreatic Cancer. download schema and patient eligibility summary
GASTROINTESTINAL OTHER:
N0747 Sutent Plus Xeloda vs Xeloda Alone for Elderly and/or Poor Performance Status Patients with Metastatic Adenocarcinoma of the Esophagus or Gastroesophageal Junction. download schema and patient eligibility summary
S0809 Adjuvant Xeloda/Gemzar Chemotherapy followed by Concurrent Xeloda and Radiotherapy in Extrahepatic Cholangiocarcinoma. download schema and patient eligibility summary
GENITOURINARY:
PROSTATE:
RTOG-0534 Short Term Androgen Deprivation with Pelvic Lymph Node or Prostate Bed Only Radiotherapy in Prostate Cancer Patients with Rising PSA After Radical Prostatectomy . download schema and patient eligibility summary
S0421 Taxotere +/- Xinlay for Patients with Advanced Hormone Refractory Prostate Cancer. download schema and patient eligibility summary
RENAL:
E2804 VEGF, RAF kinase, and mTOR Combination Targeted Therapy with Avastin, Nexavar and Torisel in Advanced Renal Cell Carcinoma. download schema and patient eligibility summary
E2805 Randomized, Double-Blind Phase III Trial of Adjuvant Sutent (Sunitinib) vs Nexavar (Sorafenib) vs Placebo in Patients with Resected Renal Cell Carconoma. download schema and patient eligibility summary
GENITOURINARY OTHER:
CALGB-90601 Gemzar, Cisplatin, Avastin vs Gemzar, Cisplatin and Placebo in Patients with Advanced Transitional Cell Carcinoma. download schema and patient eligibility summary
GYN:
CERVICAL:
GOG-0240 Cisplatin plus Taxol with/without Avastin vs Non-Platinum Doublet, Hycamtin plus Taxol, with/without Avastin, in Stage IVB, Recurrent or Persistent Carcinoma of the Cervix. download schema and patient eligibility summary
ENDOMETRIAL:
GOG-0249 Pelvic Radiation Therapy vs Vaginal Cuff Brachytherapy followed by Taxol/Carboplatin Chemotherapy in Patients with High Risk, Early Stage Endometrial Carcinoma. download schema and patient eligibility summary
GOG-0258 Cisplatin and Tumor Volume Directed Irradiation followed by Carboplatin and Taxol vs Carboplatin and Taxol for Optimally Debulked, Advanced Endometrial Carcinoma. download schema and patient eligibility summary
GYN OTHER:
GOG-0252 Avastin with IV vs IP Chemotherapy in Ovarian, Fallopian Tube and Primary Peritoneal Carcinoma. download schema and patient eligibility summary
HEAD & NECK:
20050236 Combination Chemotherapy with or without Vectibix as First-Line Treatment of Subjects with Metastatic or Recurrent Head & Neck Cancer, and Cross-Over Second-Line Vectibix Monotherapy of Subjects Who Fail the Combination Only Arm. download schema and patient eligibility summary
20062088 Second-Line Vectibix Monotherapy in Patients with Metastatic or Recurrent Squamous Cell Carcinoma of the Head & Neck. download schema and patient eligibility summary
E1305 Chemotherapy with/without Avastin in Patients with Recurrent or Metastatic Head & Neck Cancer. download schema and patient eligibility summary
LEUKEMIA:
LEUKEMIA CANCER CONTROL:
CICL670AUS22 Registry in Iron Overloaded Lower-Risk Myeolodysplastic Patients . download schema and patient eligibility summary
ALL:
CALGB-10403 Untreated Acute Lymphoblastic Leukemia. download schema and patient eligibility summary
AML:
S0703 Vidaza Plus Mylotarg as Induction and Post-Remission Therapy in Patients of Age 60 and Older with Previously Untreated Non-M3 Acute Myeloid Leukemia. download schema and patient eligibility summary
LEUKEMIA OTHER:
CALGB-10404 Three Fludara/Antibody Combinations for Patients with Symptomatic, Previously Untreated Chronic Lymphocytic Leukemia. download schema and patient eligibility summary
CALGB-10501 Asymptomatic Patients with Untreated Chronic Lymphoctyic Leukemia: Early Intervention vs Observation with Later Treatment in the High Risk Genetic Subset with IgVh Unmutated Disease. download schema and patient eligibility summary
RC0783 Nipent, Cytoxan, and Rituxan with or without Concurrent Avastin for Previously Untreated B-Chronic Lymphocytic Leukemia. download schema and patient eligibility summary
S0535 Trisenox and Mylotarg in Patients with Previously Untreated High-Risk Acute Promyelocytic Leukemia. download schema and patient eligibility summary
LEUKEMIA COMPANION:
S9910 Leukemia Central Ref Lab, Tissue Reposit download schema and patient eligibility summary
SWOG-9007 Cytogenetic Studies in Leukemia Patients
LUNG:
LUNG CANCER CONTROL:
S0424 Molecular Epidemiology Case-Series Study of NSCLC in Non-Smoking Women and Men. download schema and patient eligibility summary
NSCLC:
AC01L08 Erbitux in Combination with Platinum-based Chemotherapy as First Line Treatment of Patients with Recurrent or Advanced NSCLC. download schema and patient eligibility summary
CALGB-30506 Adjuvant Therapy in Early Stage NSCLC Evaluating the Potential Utility of a Genomic Prognostic Model to Identify Patients as Candidates for Adjuvant Chemotherapy. download schema and patient eligibility summary
CALGB-30607 Sutent as Maintenance Therapy in Non-progressing Patients Following an Initial Four Cycles of Platinum-based Combination Chemotherapy in Advanced, Stage IIIB/IV Non-Small Cell Lung Cancer. download schema and patient eligibility summary
E1505 Adjuvant Chemotherapy with or without Avastin for Patients with Completely Resected Stage IB(>=4 cm)-IIIA Non-Small Cell Lung Cancer. download schema and patient eligibility summary
N0626 Alimta with Nexavar vs Alimta Alone as Second-line Therapy in Patients with Advanced Non-Small Cell Lung Cancer. download schema and patient eligibility summary
N0723 Second-line Therapy in Patients with Advanced Non-Small Cell Lung Cancer Randomized to Alimta vs Tarceva. download schema and patient eligibility summary
N0724 Oligometastatic Stage IV NSCLC Treated with Systemic Therapy plus either Radiotherapy to all Sites of Gross Disease or No Radiotherapy. download schema and patient eligibility summary
S0709 Carboplatin/Taxol/Tarceva or Tarceva Alone in Advanced Non-Small Cell Lung Cancer Patients with Performance Status 2 Selected by Serum Proteomics. download schema and patient eligibility summary
S0720 ERCC1 and RRM1-Based Adjuvant Therapy Trial in Patients with Stage I Non-Small Cell Lung Cancer. download schema and patient eligibility summary
S0819 Carboplatin/Taxol or Carboplatin/Taxol/Avastin with/without Concurrent Erbitux in Patients with Advanced Non-Small Cell Lung Cancer. download schema and patient eligibility summary
SCLC:
CALGB-30610 Thoracic Radiotherapy Regimens in Patients with Limited Small Cell Lung Cancer Also Receiving Cisplatin and Etoposide. download schema and patient eligibility summary
S0802 Weekly Hycamtin with and without VEGF Trap in Patients with Platinum Treated Extensive Stage Small Cell Lung Cancer. download schema and patient eligibility summary
LUNG OTHER:
S0722 MTOR Inhibitor, Everolimus, in Malignant Pleural Mesothelioma. download schema and patient eligibility summary
LUNG COMPANION:
S9925 Lung Cancer Specimen Repository
LYMPHOMA:
NHL:
S0433 Bexxar in Combination with Cytoxan, Adriamycin, Vincristine, Prednisone and Rituxan Therapy for Patients with Advanced Stage Diffuse Large B-Cell NHL. download schema and patient eligibility summary
S0629 Observational Study of Asymptomatic Waldenstrom's Macroglobulinemia and Tandem Autologous Transplant and Maintenance Treatment for Patients with Symptomatic Disease. download schema and patient eligibility summary
S0801 Iodine-131 Labeled Bexxar in Combination with Cytoxan, Adriamycin, Vincristine, Prednisone and Rituxan Therapy for Patients with Advanced Stage Follicular Non-Hodgkin's Lymphoma. download schema and patient eligibility summary
HODGKIN'S:
S0816 Response Adapted Therapy of Stage III-IV Hodgkin Lymphoma Using Early Interim FDG-PET Imaging. download schema and patient eligibility summary
LYMPHOMA COMPANION:
S8947 Central Lymphoma Serum Repository Protocol
SWOG-8819 Central Lymphoma Repository Tissue Procurement Protocol
MELANOMA:
CA033 Abraxane vs Dacarbazine in Previously Untreated Patients with Metastatic Malignant Melanoma. download schema and patient eligibility summary
E1697 Four Weeks of High Dose IFN-26 in Stage T3-T4 or N1 (Microscopic) Myeloma. download schema and patient eligibility summary
N0775 Temodar and Avastin or Abraxane/Carboplatin and Avastin in Patients with Unresectable Stage IV Malignant Melanoma. download schema and patient eligibility summary
S0826 SCH 727965 in Patients with Stage IV Melanoma. download schema and patient eligibility summary
MYELOMA:
MYELOMA CANCER CONTROL:
CZOL446EUS129 Bone Marker Directed Dosing of Zometa for the Prevention of Skeletal Complications in Patients with Advanced Multiple Myeloma. download schema and patient eligibility summary
MYELOMA TREATMENT:
C05009 Three Treatment Regimens in Subjects with Previously Untreated Multiple Myeloma Who Are Not Considered Candidates for High Dose Chemotherapy and Autologous Stem Cell Transplantation: Velcade, Thalidomide, and Dexamethasone vs Velcade and Dexamethasone vs Velcade, Melphalan, and Prednisone. download schema and patient eligibility summary
E1A06 Melphalan/Prednisone/Thalidomide vs Melphalan/Prednisone/Revlimid in Newly Diagnosed Multiple Myeloma Patients Who Are Not Candidates for High-Dose Therapy. download schema and patient eligibility summary
PX-171-004 Carfilzomib in Patients with Relapsed Multiple Myeloma. download schema and patient eligibility summary
S0777 Revlimid and Low Dose Dexamethasone vs Velcade, Revlimid and Low Dose Dexamethasone for Induction, in Patients with Previously Untreated Multiple Myeloma Without an Intent for Immediate Autologous Stem Cell Transplant. download schema and patient eligibility summary
MYELOMA COMPANION:
S0309 Myeloma Specimen Repository Protocol, Ancillary download schema and patient eligibility summary
OTHER:
CALGB-70604 Standard vs Longer Dosing Interval of Zometa in Metastatic Cancer. download schema and patient eligibility summary
E2905 Major Erythroid Response to Treatment with Revlimid Alone and in Combination with Procrit in Subjects with Low- or Intermediate-1 Risk MDS and Symptomatic Anemia. download schema and patient eligibility summary
INCB 18424-351 JAK Inhibitor INCB018424 Tablets Administered Orally to Subjects with Primary Myelofibrosis, Post-Polycythemia Vera-Myelofibrosis or Essential Thrombocythemia Myelofibrosis. download schema and patient eligibility summary
N0392 Assessment of Patient Satisfaction with Participation on Phase II/III NCCTG Clinical Trials. download schema and patient eligibility summary
